Actions Panel
CDRD Symposium: Novel Strategies in Cancer Immunotherapy
When and where
Date and time
Fri, May 26, 2017 8:30 AM - 2:00 PM PDT
Location
CDRD Headquarters UBC Pharmaceutical Sciences Building 2405 Wesbrook Mall Vancouver, BC V6T 1Z3 Canada
Description
CDRD, Canada's national drug development and commercialization engine, is hosting a symposium "Novel strategies in cancer immunotherapy." Full event details at: www.cdrd.ca/events/immunotherapy/
Join us and top cancer researchers and clinicians from across Canada to learn about recent advances in immunotherapy, outcomes, lessons learned and discuss where we are headed.
The agenda includes short and concise talks, a moderated panel discussion, and opportunities to network and explore potential partnerships and collaborations.
There is no charge to attend. Breakfast and lunch will be provided.
Agenda:
8:30 – 8:45am: Continental breakfast
8:50 – 9:00am: Welcoming remarks and brief overview of CDRD Immunotherapy Initiative
9:00 – 9:40am: “The power of the fish for immunotherapy research” - Dr. Jason Berman (MSC Clinician Scientist in Pediatric Oncology, IWK Health Centre)
9:40 – 10:00am: Dr. Brad Nelson (Director and Distinguished Scientist, Deeley Research Centre, BC Cancer Agency)
10:00 – 10:20am: Dr. Rebecca Auer (Scientist, Cancer Therapeutics Program, Ottawa Hospital Research Institute)
10:20 – 10:50am: Coffee break and networking
10:50 – 11:10am: Dr. Carl Hansen (CEO & President, Co-Founder, AbCellera)
11:10 – 11:30am: Dr. Rob Holt (Distinguished Scientist, BC Cancer Agency)
11:30 – 11:50am: Dr. Thomas Kislinger (Senior Scientist, Princess Margaret Cancer Centre)
11:50am – 12:50pm: Peter Klein (UBC), Moderated Panel Discussion, Q&A session
12:50 – 1:50pm: Networking lunch
About the organizer
CDRD is Canada’s national life sciences venture, powering the country’s life sciences industry by creating and growing companies of scale – while training the scientific and business talent needed to drive them to become leading global anchors for Canada.
We build collaborations with the very best partners from academia, industry, patient foundations, the investment community, and other key opinion leaders to provide the specialized expertise and infrastructure to identify, validate and advance promising discoveries, and transform them into commercially viable investment opportunities for the private sector — and ultimately into new therapies for patients.